Publicaciones en las que colabora con PATRICIA PALAU SAMPIO (96)

2024

  1. Baseline resting heart rate and responsiveness to a home-based inspiratory muscle training program in long COVID

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 344-347

  2. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 167-176

  3. Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trial

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 15, Núm. 2, pp. 681-689

  4. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

  5. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  2. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  3. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  4. Maximal functional capacity in subjects with isolated left bundle branch block: A pilot study

    Clinical Cardiology, Vol. 46, Núm. 4, pp. 386-389

  5. Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 264-273

  6. Role of plasma carbohydrate antigen 125 to identify nonfrail patients in HF

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 172-179

  7. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  8. Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction

    Journal of Cardiac Failure, Vol. 29, Núm. 5, pp. 849-854

  9. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Beta-blockers and renin–angiotensin–aldosterone system inhibitors in HFpEF. An urgent need for precision medicine

    REC: CardioClinics, Vol. 57, Núm. 3, pp. 162-164

  2. Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

    Scientific Reports, Vol. 12, Núm. 1

  3. Combined assessment of stress cardiovascular magnetic resonance and angiography to predict the effect of revascularization in chronic coronary syndrome patients

    European Journal of Preventive Cardiology, Vol. 29, Núm. 2, pp. 407-416

  4. Effect of a home-based inspiratory muscle training programme on functional capacity in postdischarged patients with long COVID: The InsCOVID trial

    BMJ Open Respiratory Research, Vol. 9, Núm. 1

  5. Effect of a home-based inspiratory muscular training programme on functional capacity in patients with chronic COVID-19 after a hospital discharge: Protocol for a randomised control trial (InsCOVID trial)

    BMJ Open Respiratory Research, Vol. 9, Núm. 1

  6. Iron deficiency testing in acute heart failure. Much to do

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 296-299